Mylan's Bertek unit licenses nebivolol
Bertek Pharmaceuticals, the branded products division of generics houseMylan Laboratories, has licensed exclusive US and Canadian rights to nebivolol, a beta blocker originally developed by Johnson & Johnson's Janssen Pharmaceutica.
The drug is already on the market in 30 countries in Europe and Central America, but Bertek believes it has a clinical profile, notably a high degree of beta1 receptor selectivity and an effect on nitric oxide-dependent vasodilation, which makes it unique among its therapeutic class, with particular activity in African American patients. The company plans to start clinical trials shortly in both hypertension and heart failure, with a view to filing for approval in the USA in 2003.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze